Brief: Clene Inc FDA Confirms Als Survival Data Type C Meeting & End-Of-Phase 2 Type B MS Program Meeting For Q3 2025
30/06/2025 13:23
Clene Inc. CLNN.O: CLENE INC: FDA CONFIRMS ALS SURVIVAL DATA TYPE C MEETING & END-OF-PHASE 2 TYPE B MS PROGRAM MEETING FOR Q3 2025 Source text: ID:nGNX45gB20 Further company coverage: CLNN.O
Recent news on Clene
See all newsClene Inc reports results for the quarter ended June 30 - Earnings Summary
Clene Q2 net loss widens on higher other expenses
Clene Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Clene Inc - Enters Second Amendment To Senior Secured Convertible Notes - SEC Filing
Clene Q1 loss widens on warrant liability issuance costs